

# Ziping Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1425429/publications.pdf>

Version: 2024-02-01

40  
papers

652  
citations

758635

12  
h-index

676716

22  
g-index

42  
all docs

42  
docs citations

42  
times ranked

670  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. <i>Lancet Oncology</i> , The, 2022, 23, 220-233.	5.1	106
2	Significant Upregulation of HERV-K (HML-2) Transcription Levels in Human Lung Cancer and Cancer Cells. <i>Frontiers in Microbiology</i> , 2022, 13, 850444.	1.5	8
3	The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-mutant Non-small Cell lung cancer. <i>Cancer Medicine</i> , 2022, 11, 3581-3592.	1.3	10
4	Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung. <i>Thoracic Cancer</i> , 2022, 13, 442-452.	0.8	4
5	A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9019-9019.	0.8	10
6	The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8572-8572.	0.8	4
7	Abstract CT554: Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study. <i>Cancer Research</i> , 2022, 82, CT554-CT554.	0.4	0
8	Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9096-9096.	0.8	6
9	A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9027-9027.	0.8	2
10	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , 2021, 9, 33-33.	0.7	16
11	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. <i>Translational Lung Cancer Research</i> , 2021, 10, 981-994.	1.3	17
12	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage IIIA non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2021, 13, 1799-1812.	0.6	4
13	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. <i>Journal of Thoracic Disease</i> , 2021, 13, 1813-1821.	0.6	3
14	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma: A Retrospective Analysis of a Multicenter Clinical Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 639892.	1.6	7
15	Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC). <i>Cancer Research</i> , 2021, 81, CT041-CT041.	0.4	3
16	Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1959-1963.	0.5	7
17	Abstract CT039: Results from RATIONALE 303: A global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC. <i>Cancer Research</i> , 2021, 81, CT039-CT039.	0.4	10
18	Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1617.	3.4	105

#	ARTICLE	IF	CITATIONS
19	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 892-901.	3.2	80
20	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. <i>BMC Cancer</i> , 2020, 20, 666.	1.1	22
21	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. <i>Frontiers in Oncology</i> , 2020, 10, 1137.	1.3	7
22	The adverse events associated with combination immunotherapy in cancers: Challenges and chances. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e154-e159.	0.7	11
23	Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. <i>BMC Cancer</i> , 2020, 20, 793.	1.1	12
24	Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1584.	1.3	15
25	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , 2020, 20, 590.	1.8	0
26	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1015-1026.	0.5	58
27	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. <i>Frontiers in Oncology</i> , 2020, 10, 626.	1.3	17
28	Characteristics and Outcomes of a Sample of Patients With COVID-19 Identified Through Social Media in Wuhan, China: Observational Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e20108.	2.1	20
29	Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. <i>Thoracic Cancer</i> , 2019, 10, 1788-1797.	0.8	10
30	Optimal first-line treatment for advanced thymic carcinoma. <i>Thoracic Cancer</i> , 2019, 10, 2081-2087.	0.8	11
31	Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. <i>Thoracic Cancer</i> , 2019, 10, 1193-1202.	0.8	12
32	A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. <i>Lung Cancer</i> , 2019, 130, 135-142.	0.9	10
33	Survival comparison of right and left side non-small cell lung cancer in stage I-IIIa patients: A Surveillance Epidemiology and End Results (SEER) analysis. <i>Thoracic Cancer</i> , 2019, 10, 459-471.	0.8	14
34	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018, 9, 291-297.	0.8	5
35	Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study). <i>Thoracic Cancer</i> , 2018, 9, 1795-1800.	0.8	3
36	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1166-1173.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIa non-small cell lung cancer patients.. Journal of Clinical Oncology, 2018, 36, 8524-8524.	0.8	0
38	Survival in right-sided versus left-sided stage IB-IIIa non-small cell lung cancer patients.. Journal of Clinical Oncology, 2018, 36, e20509-e20509.	0.8	0
39	Population-based study predicting the probability of death resulting from non-small cell lung cancer (NSCLC) and other causes among NSCLC patients with surgery.. Journal of Clinical Oncology, 2018, 36, 8525-8525.	0.8	0
40	Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 553-560.	0.7	13